Maqsood Javed, MD
Internal Medicine · Houston, TXNPI 1073568713
Payments from drug & device makers
Across 259 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$933
- Novo Nordisk$589
- AstraZeneca$462
- Amarin Pharma, Inc.$362
- Amgen$266
- Astellas Pharma US Inc$180
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,14995%
- Education$1965%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 57 | $933 |
| Novo Nordisk | 34 | $589 |
| AstraZeneca | 21 | $462 |
| Amarin Pharma, Inc. | 34 | $362 |
| Amgen(2 entities) | 14 | $266 |
| Astellas Pharma US Inc | 10 | $180 |
| Lilly USA, LLC | 10 | $169 |
| Sanofi-aventis U.S. LLC | 12 | $156 |
| Boehringer Ingelheim | 8 | $155 |
| Pfizer | 7 | $127 |
| Bayer | 5 | $124 |
| Exact Sciences | 5 | $74 |
| Abbott | 3 | $65 |
| AbbVie(2 entities) | 4 | $64 |
| Dexcom, Inc. | 3 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Novartis | 3 | $55 |
| Sunovion Pharmaceuticals Inc. | 5 | $51 |
| Johnson & Johnson | 3 | $47 |
| Mylan Specialty L.p. | 2 | $46 |
| Philips North America LLC | 2 | $36 |
| Boston Scientific | 1 | $35 |
| Abiomed | 1 | $29 |
| Corcept Therapeutics | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Shield Therapeutics Inc | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Averitas Pharma Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Merck | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$4,345 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 162 | $220,547 |
| MounjaroTirzepatide | 120 | $168,846 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $63,861 |
| FarxigaDapagliflozin Propanediol | 46 | $61,415 |
| EliquisApixaban | 62 | $61,333 |
| JanuviaSitagliptin Phosphate | 30 | $38,064 |
| LinzessLinaclotide | 38 | $31,328 |
| TradjentaLinagliptin | 36 | $29,670 |
| JardianceEmpagliflozin | 23 | $28,437 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $22,920 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $19,089 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $9,615 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,516 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $8,002 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $6,963 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $589 | $220,547162 claims |
| Lilly USA, LLCMounjaro | $169 | $168,846120 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $462 | $77,99394 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $933 | $72,37796 claims |
| Boehringer IngelheimTradjenta, Jardiance, Combivent Respimat | $155 | $66,11076 claims |
| PfizerEliquis | $127 | $61,33362 claims |
| MerckJanuvia, Janumet Xr | $13 | $57,15347 claims |
| AbbVieLinzess, Synthroid | $64 | $33,75370 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.